P. Charef

发表

Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial

C. Bodemer, K. Kingo, A. Kaszuba, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study

K. Schäkel, I. Hampele, B. Sigurgeirsson, 2021, The Journal of dermatological treatment.

Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients

B. Sigurgeirsson, R. Woessner, H. Hockey, 2020, British journal of clinical pharmacology.

Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

Q. Guo, Ruo-yu Li, Hao Cheng, 2020, Chinese medical journal.

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

T. Luger, U. Mrowietz, R. Bissonnette, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection

T. Louie, D. Gerding, M. Wilcox, 2015, The Journal of antimicrobial chemotherapy.

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection

T. Louie, D. Gerding, M. Wilcox, 2015, Antimicrobial Agents and Chemotherapy.

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection

T. Louie, D. Gerding, G. Talbot, 2015 .

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial *

K. Reich, M. Augustin, G. Bruin, 2022, The British journal of dermatology.

Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.

I. Hampele, K. Reich, J. Szepietowski, 2022, The British journal of dermatology.

Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test

D. Furst, P. Emery, A. Wells, 2006, Annals of the rheumatic diseases.

Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

P. Emery, A. Wells, C. Denton, 2010, Arthritis and rheumatism.

Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects.

J. Dingemanse, J. Black, P. Charef, 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Dual Orexin Receptor Antagonist, Almorexant, in Elderly Patients With Primary Insomnia: A Randomized, Controlled Study

T. Roth, G. Zammit, R. Cluydts, 2017, Sleep.